RCUS

Bearish

Is Trial Failures And Gilead Pullback Altering The Investment Case For Arcus Biosciences (RCUS)?

Arcus Biosciences (RCUS) faces a re-evaluation of its investment case after discontinuing two Phase 2/3 lung cancer studies and Gilead Sciences narrow...

Simply Wall Street 1 week ago 0

Neutral

Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last?

Arcus Biosciences (RCUS) stock rose 7.8% on impressive volume due to investor confidence in its pipeline candidates for cancer. Despite this, the comp...

Yahoo! Finance Canada 2 weeks ago 0